Antibody Response to Human Papillomavirus Recombinant Vaccine (Gardasil) in Girls and Young Women With Chronic Kidney Disease

Trial Profile

Antibody Response to Human Papillomavirus Recombinant Vaccine (Gardasil) in Girls and Young Women With Chronic Kidney Disease

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
  • Indications Cervical cancer; Human papillomavirus infections
  • Focus Pharmacodynamics
  • Most Recent Events

    • 01 Sep 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 26 May 2010 Planned number of patients changed from 45 to 60 as reported by ClinicalTrials.gov.
    • 26 May 2010 Planned end date changed from 1 Aug 2010 to 1 Jun 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top